A Safety and Pharmacokinetics Study of TL-003 in Healthy Adults and Open-label Assessments in Participants With Ulcerative Colitis

Phase 1 Recruiting 48 enrolled TrueLab Biopharmaceutical Co., Ltd SAPRO Consulting Pty Ltd · collab

RandomizedSequentialDouble-blindTreatment

Summary

The goal of this study is to evaluate safety, tolerability, pharmacokinetics (PK)), pharmacodynamics (PD) and immunogenicity of single and multiple ascending dose of TL-003 in healthy adult participants.

Timeline

Start: 2026-04-08
Primary completion: 2027-04
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TL-003	Unknown	—	Intravenous

Indications

No indication recorded.